Allovir Inc reports results for the quarter ended in June - Earnings Summary

Kalaris Therapeutics

03/08/2023 14:07

* Allovir Inc  ALVR.OQ  reported a quarterly adjusted loss
of 48
cents​​ per share for the quarter ended in June. The mean
expectation of four analysts for the quarter was for a loss
of 44 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Allovir Inc's reported EPS for the quarter was a loss
of 48
cents​.
    * The mean earnings estimate of analysts had risen by
about 7% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Allovir Inc shares had fallen by 11.2% this quarter and
lost 41.1% so far this year.
    * The company reported a quarterly loss of $45.27 million.
    * Wall Street's median 12-month price target for Allovir Inc
is
$20.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 3 at 01:06 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.44          -0.48          Missed
 Mar. 31 2023      -0.46          -0.44          Beat
 Dec. 31 2022      -0.54          -0.37          Beat
 Sep. 30 2022      -0.53          -0.50          Beat